Log in

NASDAQ:TOCA - Tocagen Stock Price, Forecast & News

$0.56
+0.03 (+5.61 %)
(As of 01/17/2020 07:42 AM ET)
Add
Compare
Today's Range
$0.54
Now: $0.56▼
$0.60
50-Day Range
$0.44
MA: $0.55▼
$0.72
52-Week Range
$0.42
Now: $0.56▼
$12.00
Volume741,795 shs
Average Volume673,615 shs
Market Capitalization$13.49 million
P/E RatioN/A
Dividend YieldN/A
Beta3.79
Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TOCA
Previous Symbol
CUSIPN/A
CIK1419041
Webhttp://www.tocagen.com/
Phone858-412-8400

Debt

Debt-to-Equity Ratio0.46
Current Ratio1.43
Quick Ratio1.43

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$18.04 million
Price / Sales0.75
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.91 per share
Price / Book0.19

Profitability

EPS (Most Recent Fiscal Year)($2.44)
Net Income$-48,960,000.00
Net Margins-201,488.91%
Return on Equity-182.15%
Return on Assets-82.01%

Miscellaneous

Employees77
Outstanding Shares23,898,000
Market Cap$13.49 million
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive TOCA News and Ratings via Email

Sign-up to receive the latest news and ratings for TOCA and its competitors with MarketBeat's FREE daily newsletter.

NASDAQ:TOCA Rates by TradingView

Investor Alert: 3 Top Stocks for Next Week Revealed NOW (Ad)


Each week, an exclusive group of investors receives access to a simple list of 3 stocks to put on their radar for the week ahead.

You can sign up today to receive access to next week's watchlist -- generated by a proprietary methodology -- at no cost or obligation.

Tocagen (NASDAQ:TOCA) Frequently Asked Questions

What is Tocagen's stock symbol?

Tocagen trades on the NASDAQ under the ticker symbol "TOCA."

How were Tocagen's earnings last quarter?

Tocagen Inc (NASDAQ:TOCA) posted its earnings results on Tuesday, November, 12th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.68) by $0.10. The business had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.01 million. Tocagen had a negative return on equity of 182.15% and a negative net margin of 201,488.91%. View Tocagen's Earnings History.

When is Tocagen's next earnings date?

Tocagen is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Tocagen.

What price target have analysts set for TOCA?

9 Wall Street analysts have issued twelve-month price objectives for Tocagen's shares. Their forecasts range from $1.00 to $28.00. On average, they anticipate Tocagen's share price to reach $9.90 in the next twelve months. This suggests a possible upside of 1,654.6% from the stock's current price. View Analyst Price Targets for Tocagen.

What is the consensus analysts' recommendation for Tocagen?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tocagen in the last year. There are currently 9 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Tocagen.

What are Wall Street analysts saying about Tocagen stock?

Here are some recent quotes from research analysts about Tocagen stock:
  • 1. According to Zacks Investment Research, "Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company which focuses on retroviral gene therapy platforms. The company's lead product candidate consists of Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma, a disease with a significant unmet medical need. Tocagen, Inc. is based in San Diego, United States. " (1/15/2020)
  • 2. HC Wainwright analysts commented, "We lower our rating of TOCA to and considering the limited visibility of company’s pipeline development strategy going forward, we are not comfortable to determine a specific price target. (1) clinical; (2) commercial; (3) partnership; (4) financial; and (5) intellectual property. Tocagen, Inc. September 12, 2019 H.C. WAINWRIGHT & CO." (9/12/2019)

Has Tocagen been receiving favorable news coverage?

News stories about TOCA stock have been trending positive on Friday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Tocagen earned a coverage optimism score of 3.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Tocagen.

Are investors shorting Tocagen?

Tocagen saw a decrease in short interest in December. As of December 31st, there was short interest totalling 2,020,000 shares, a decrease of 14.4% from the December 15th total of 2,360,000 shares. Based on an average daily volume of 537,500 shares, the days-to-cover ratio is currently 3.8 days. Approximately 9.2% of the company's shares are short sold. View Tocagen's Current Options Chain.

Who are some of Tocagen's key competitors?

What other stocks do shareholders of Tocagen own?

Who are Tocagen's key executives?

Tocagen's management team includes the folowing people:
  • Mr. Martin J. Duvall, CEO & Director (Age 57)
  • Mr. Thomas E. Darcy, Co-Founder & Director (Age 68)
  • Dr. Douglas J. Jolly, Co-Founder and Exec. VP of Research & Pharmaceutical Devel. (Age 71)
  • Mr. Mark G. Foletta C.P.A., CPA, Exec. VP & CFO (Age 58)
  • Dr. Harry E. Gruber, Founder, Adviser & Director (Age 66)

When did Tocagen IPO?

(TOCA) raised $80 million in an initial public offering on Thursday, April 13th 2017. The company issued 7,300,000 shares at $10.00-$12.00 per share. Leerink Partners, Evercore ISI and Stifel served as the underwriters for the IPO.

How do I buy shares of Tocagen?

Shares of TOCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Tocagen's stock price today?

One share of TOCA stock can currently be purchased for approximately $0.56.

How big of a company is Tocagen?

Tocagen has a market capitalization of $13.49 million and generates $18.04 million in revenue each year. The company earns $-48,960,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis. Tocagen employs 77 workers across the globe.View Additional Information About Tocagen.

What is Tocagen's official website?

The official website for Tocagen is http://www.tocagen.com/.

How can I contact Tocagen?

Tocagen's mailing address is 4242 CAMPUS POINT COURT SUITE 500, SAN DIEGO CA, 92121. The company can be reached via phone at 858-412-8400 or via email at [email protected]


MarketBeat Community Rating for Tocagen (NASDAQ TOCA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  220 (Vote Outperform)
Underperform Votes:  229 (Vote Underperform)
Total Votes:  449
MarketBeat's community ratings are surveys of what our community members think about Tocagen and other stocks. Vote "Outperform" if you believe TOCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TOCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2020 by MarketBeat.com Staff

Featured Article: Dividend Stocks - Are They Right For You?
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel